Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
CSL Behring
Timothy J Craig; Avner Reshef; H Henry Li; Joshua S Jacobs; Jonathan A Bernstein; Henriette Farkas; William H Yang; Erik S G Stroes; Isao Ohsawa; Raffi Tachdjian; Michael E Manning; William R Lumry; Inmaculada Martinez Saguer; Emel Aygören-Pürsün; Bruce Ritchie; Gordon L Sussman; John Anderson; Kimito Kawahata; Yusuke Suzuki; Petra Staubach; Regina Treudler; Henrike Feuersenger; Fiona Glassman; Iris Jacobs; Markus Magerl